pteridines has been researched along with gs-9620 in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 29 (80.56) | 24.3611 |
| 2020's | 7 (19.44) | 2.80 |
| Authors | Studies |
|---|---|
| Brasky, KM; Chavez, D; Fosdick, A; Frey, CR; Giavedoni, L; Guerra, B; Halcomb, RL; Hodara, VL; Lanford, RE; Tumas, DB; Wolfgang, G; Zheng, J | 1 |
| Frey, CR; Hesselgesser, J; Kearney, B; Lopatin, U; McHutchison, JG; Moorehead, L; Ohmstede, C; Subramanian, GM; Tumas, D; Wolfgang, G | 1 |
| Rosania, K | 1 |
| Durantel, D; Luangsay, S; Zoulim, F | 1 |
| Fosdick, A; Frey, CR; Halcomb, RL; Hesselgesser, J; Pflanz, S; Tumas, DB; Wolfgang, G; Zheng, J | 1 |
| Freilich, B; Gaggar, A; Gruener, D; Hassman, D; Hill, J; Jacobson, IM; Lawitz, E; Marbury, T; Massetto, B; McHutchison, JG; Mogalian, E; Nguyen, AH; Pflanz, S; Rodriguez-Torres, M; Subramanian, GM; Webster, L | 1 |
| AlDeghaither, D; Baldwin, BH; Bellezza, CA; Cote, PJ; Daffis, S; Fletcher, SP; Fosdick, A; Halcomb, R; Li, L; Liu, KH; Menne, S; Tennant, BC; Thampi, L; Tumas, DB; Wolfgang, GH; Yue, P; Zheng, J | 1 |
| Cheng, W; Coffin, CS; Fedorak, RN; Freilich, B; Gaggar, A; Gane, EJ; Garrison, KL; Gordon, SC; Kim, YJ; Kottilil, S; Lim, YS; Mani Subramanian, G; Massetto, B; McHutchison, JG; Pflanz, S; Roberts, S; Sicard, E; Visvanathan, K; Ye, Z | 1 |
| Cohen, J | 1 |
| Janssen, HL; van Campenhout, MJ | 1 |
| Birkus, G; Kwon, H; Perry, J; Pflanz, S; Rebbapragada, I; Xing, W | 1 |
| Arbuthnot, P; Lamb, C | 1 |
| Bam, RA; Cihlar, T; Frey, CR; Hansen, D; Hesselgesser, J; Irrinki, A; Jones, GS; Mulato, A; Yant, SR | 1 |
| Cihlar, T; Irrinki, A; Kaur, J; Kukolj, G; Murry, JP; Sloan, DD; Tsai, A | 1 |
| Ahn, SH; Brunetto, MR; Ferrari, C; Fung, S; Gaggar, A; Gane, EJ; Janssen, HLA; Joshi, A; Kim, YJ; Lau, AH; Massetto, B; Nguyen, AH; Subramanian, GM; Tsai, NCS; Woo, J; Yoshida, EM | 1 |
| Barry, V; Daffis, S; Delaney, WE; Fletcher, SP; French, DM; Huntzicker, E; Lanford, RE; Li, L; Mikaelian, I; Niu, C | 1 |
| Balsitis, S; Beran, RK; Bonnin, M; Chu, R; Daffis, S; Delaney, WE; Durantel, D; Fletcher, SP; Garg, AV; Li, L; Livingston, CM; Lucifora, J; Maadadi, S; Niu, C; Ramos, H; Salas, E; Zoulim, F | 1 |
| Alfieri, A; Boni, C; Brunetto, MR; Cavallone, D; Coco, B; Facchetti, F; Ferrari, C; Gaggar, A; Giuberti, T; Grossi, G; Laccabue, D; Lampertico, P; Lau, A; Mangia, A; Piazzolla, V; Rossi, M; Santoro, R; Subramanian, GM; Vecchi, A | 1 |
| Bengsch, B; Thimme, R | 1 |
| Chen, X; Han, Y; Li, G; Liu, J; Qin, C; Song, N; Wu, J; Yu, P; Zhang, Q; Zhao, B | 1 |
| Enosi Tuipulotu, D; Lun, JH; Mackenzie, JM; Netzler, NE; White, PA | 1 |
| Barnes, TL; Cihlar, T; Geleziunas, R; Gerold, JM; Hesselgesser, J; Hill, AL; Hraber, PT; Lee, WA; Lewis, MG; Lim, SY; Miller, MD; Osuna, CE; Sanisetty, S; Seaman, MS; Whitney, JB | 1 |
| Agarwal, K; Ahn, SH; Andreone, P; Bulusu, A; Cathcart, AL; Chuang, WL; Elkhashab, M; Gaggar, A; Kim, HJ; Lau, AH; Nguyen, MH; Subramanian, GM; Tian, X; Woo, J | 1 |
| Hu, F; Li, W; Wang, Y; Zhang, J; Zhang, Y | 1 |
| Bosque, A; De Assis, CM; Huang, SH; Jones, RB; Macedo, AB; Moszczynski, P; Novis, CL; Planelles, V; Ren, Y; Sorensen, ES; Spivak, AM | 1 |
| Abbink, P; Alter, G; Barouch, DH; Bekerman, E; Borducchi, EN; Broge, T; Cadena, AM; Chandrashekar, A; Fischinger, S; Geleziunas, R; Hesselgesser, J; Jetton, D; Lewis, MG; Li, W; Liu, J; McMahan, K; Mercado, NB; Moseley, ET; Nkolola, JP; Peter, L; Yu, WH | 1 |
| Alvord, WG; Barnes, TL; Berkemeier, B; Bosche, WJ; Breed, MW; Chipriano, E; Coalter, V; Del Prete, GQ; Deleage, C; Estes, JD; Fast, R; Geleziunas, R; Hesselgesser, J; Hull, M; Kiser, J; Kiser, R; Kramer, J; Li, Y; Lifson, JD; Malys, T; Nag, M; Oswald, K; Pyle, C; Silipino, L; Thomas, JA; Trubey, CM; Wiles, A; Wiles, R | 1 |
| Agarwal, K; Gane, E; Janssen, HLA; Nader, F; Nguyen, MH; Papatheodoridis, G; Stepanova, M; Tsai, N; Younossi, I; Younossi, ZM | 1 |
| Bekerman, E; Carr, B; Elyard, HA; Geleziunas, R; Hesselgesser, J; Hung, M; Lifson, JD; Nagel, M; Stapleton, L; von Gegerfelt, A; Wang, A | 1 |
| Abram, M; Callebaut, C; Duatschek, P; Geleziunas, R; Hesselgesser, J; Margot, N; Ram, RR | 1 |
| Gunst, JD; Højen, JF; Martinsen, JT; Søgaard, OS; Tolstrup, M | 1 |
| Kato, Y; Konnai, S; Maekawa, N; Murata, S; Nakamura, H; Ohashi, K; Okagawa, T; Sajiki, Y; Suzuki, Y | 1 |
| Begley, R; Benson, CA; Boice, J; Brainard, DM; Brinson, C; Cyktor, J; DeJesus, E; Geleziunas, R; German, P; Graham, H; Guo, S; Humeniuk, R; Jacobs, J; Koontz, D; Laird, GM; Mellors, JW; Mills, A; Para, M; Patel, H; Ramgopal, M; Riddler, SA; SenGupta, D; Wallin, J; Wrin, T; Zhang, L | 1 |
| Acikelli, AH; Andrioff, S; D'Souza, F; Dammann, P; Demmig, R; Díaz-Carballo, D; Erwes, J; Grandi, N; Homp, E; Klein, D; Klein, J; Malak, S; Menze, S; Nasreen, A; Noa-Bolaño, A; Ochsenfarth, C; Pano, E; Saka, S; Schröer, K; Strumberg, D; Tannapfel, A; Teipel, M; Tramontano, E | 1 |
| Begley, R; Brainard, DM; Brinson, C; Cai, Y; Deeks, SG; DeJesus, E; Ferre, AL; Geleziunas, R; Guo, S; Humeniuk, R; Jones, N; Laird, GM; Mellors, J; Mills, A; Milush, J; Moldt, B; Ramgopal, M; SenGupta, D; Shacklett, BL; Shalit, P; Vendrame, E; Wallin, JJ; Wrin, T; Zhang, L | 1 |
| Kang, HR; Kim, A; Kim, SM; Lee, G; Lee, MJ; Park, JH | 1 |
3 review(s) available for pteridines and gs-9620
| Article | Year |
|---|---|
How to achieve immune control in chronic hepatitis B?
Topics: Antiviral Agents; Biomarkers; DNA, Circular; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunomodulation; Interferon-alpha; Interleukins; Lamivudine; Polyethylene Glycols; Pteridines; Telbivudine; Thymidine | 2015 |
Activating the innate immune response to counter chronic hepatitis B virus infection.
Topics: Animals; Antiviral Agents; DNA Replication; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunity, Innate; Immunomodulation; Pteridines; Toll-Like Receptor 7; Virus Replication | 2016 |
The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Topics: Adjuvants, Immunologic; AIDS Vaccines; Animals; Anti-HIV Agents; Broadly Neutralizing Antibodies; Clinical Trials as Topic; HIV Antibodies; HIV Infections; HIV-1; Humans; Immune Checkpoint Inhibitors; Immunologic Factors; Immunotherapy; In Vitro Techniques; Models, Immunological; Primates; Pteridines; Toll-Like Receptor 3; Toll-Like Receptor 7; Toll-Like Receptor 9; Toll-Like Receptors; Virus Latency | 2020 |
9 trial(s) available for pteridines and gs-9620
| Article | Year |
|---|---|
Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist.
Topics: Administration, Oral; Adult; Antiviral Agents; Cytokines; Female; Humans; Male; Pteridines; Toll-Like Receptor 7; Ubiquitins; Young Adult | 2013 |
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Cytokines; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pteridines; RNA, Messenger; Toll-Like Receptor 7; Treatment Outcome; Ubiquitins; Viral Load; Young Adult | 2015 |
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Pteridines; Retrospective Studies; Toll-Like Receptor 7; Treatment Outcome; Young Adult | 2015 |
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.
Topics: Adaptive Immunity; Administration, Oral; Adult; Antiviral Agents; Double-Blind Method; Drug Monitoring; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunity, Innate; Male; Middle Aged; Monitoring, Immunologic; Pteridines; Toll-Like Receptor 7; Treatment Outcome | 2018 |
TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Killer Cells, Natural; Male; Middle Aged; Nucleosides; Prospective Studies; Pteridines; T-Lymphocytes; Toll-Like Receptor 7 | 2018 |
Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.
Topics: Adult; Aged; Antiviral Agents; Cytokines; DNA, Viral; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pteridines; Seroconversion; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2018 |
Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Internationality; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Pteridines; Quality of Life; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome; Viral Load; Virus Replication | 2019 |
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1.
Topics: Antiviral Agents; Double-Blind Method; HIV Infections; HIV-1; Humans; Pteridines; Toll-Like Receptor 7 | 2021 |
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy.
Topics: Animals; Anti-Retroviral Agents; HIV Infections; Humans; Pteridines; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Toll-Like Receptor 7; Viral Load | 2021 |
24 other study(ies) available for pteridines and gs-9620
| Article | Year |
|---|---|
GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
Topics: Administration, Oral; Animals; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Immunity, Innate; Immunologic Factors; Pan troglodytes; Pteridines; Toll-Like Receptor 7; Viral Load | 2013 |
Relying on chimpanzees for hepatitis research.
Topics: Animal Use Alternatives; Animals; Antiviral Agents; Disease Models, Animal; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver; Pan troglodytes; Pteridines; Rodentia | 2013 |
Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B.
Topics: Animals; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Immunologic Factors; Pteridines; Toll-Like Receptor 7; Viral Load | 2013 |
Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses.
Topics: Administration, Oral; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Interferon-alpha; Macaca fascicularis; Mice; Pteridines; Toll-Like Receptor 7 | 2014 |
Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B.
Topics: Animals; Antiviral Agents; Disease Models, Animal; DNA, Viral; Hepatitis Antibodies; Hepatitis Antigens; Hepatitis B; Hepatitis B Virus, Woodchuck; Humans; Liver Neoplasms, Experimental; Male; Marmota; Pteridines; Seroconversion; Time Factors; Toll-Like Receptor 7; Treatment Outcome | 2015 |
Drug flushes out hidden AIDS virus.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-HIV Agents; Antiviral Agents; HIV-1; Humans; Macaca mulatta; Pteridines; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Toll-Like Receptor 7 | 2015 |
Molecular Determinants of GS-9620-Dependent TLR7 Activation.
Topics: Amino Acid Sequence; Binding Sites; Cells, Cultured; HEK293 Cells; Humans; Molecular Sequence Data; Mutation; Polymorphism, Single Nucleotide; Protein Binding; Pteridines; Toll-Like Receptor 7 | 2016 |
TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells.
Topics: Antibodies; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Interferon-alpha; Interferons; Interleukin-6; Leukocytes, Mononuclear; Macrophages; Pteridines; Toll-Like Receptor 7; Virus Replication | 2017 |
Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
Topics: Anti-Retroviral Agents; Antibody-Dependent Cell Cytotoxicity; CD8-Positive T-Lymphocytes; Cell Differentiation; HIV; HIV Infections; Humans; Immunologic Factors; Interferon Type I; Lymphocyte Activation; Phagocytes; Pteridines; RNA, Viral; Toll-Like Receptor 7; Viral Load; Virus Activation | 2017 |
Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells.
Topics: Animals; Antiviral Agents; B-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Aggregation; Disease Models, Animal; Gene Expression Profiling; Hepatitis B, Chronic; Humans; Liver; Pan troglodytes; Pteridines; Toll-Like Receptor 7 | 2018 |
Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Topics: Animals; Antigen Presentation; Antiviral Agents; Cells, Cultured; Cytokines; DNA, Circular; DNA, Viral; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Immunity, Innate; Interferon Type I; Pteridines; RNA, Messenger; RNA, Viral; Toll-Like Receptor 7 | 2018 |
For whom the interferons toll - TLR7 mediated boosting of innate and adaptive immunity against chronic HBV infection.
Topics: Adaptive Immunity; B-Lymphocytes; Hepatitis B virus; Interferons; Pteridines; T-Lymphocytes; Toll-Like Receptor 7 | 2018 |
GS-9620 inhibits enterovirus 71 replication mainly through the NF-κB and PI3K-AKT signaling pathways.
Topics: Animals; Antiviral Agents; Cytokines; Disease Models, Animal; Enterovirus A, Human; Hand, Foot and Mouth Disease; Mice; NF-kappa B; Phosphatidylinositol 3-Kinases; Pteridines; Signal Transduction; Treatment Outcome; Virus Replication | 2018 |
TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation.
Topics: Aminoquinolines; Animals; Antiviral Agents; Caliciviridae Infections; Cell Line; Guanosine; Humans; Imidazoles; Imiquimod; Mice; Pteridines; RAW 264.7 Cells; Toll-Like Receptor 7; Virus Replication | 2018 |
TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy.
Topics: Animals; Anti-Retroviral Agents; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Macaca mulatta; Male; Pteridines; Simian Immunodeficiency Virus; Toll-Like Receptor 7; Viremia | 2018 |
Metabolism of vesatolimod in rat, dog, and human liver microsomes: Metabolic stability assessment, metabolite identification, and interspecies comparison.
Topics: Animals; Dogs; Humans; Microsomes, Liver; Pteridines; Rats; Species Specificity; Time Factors | 2019 |
Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Dendritic Cells; Drug Evaluation, Preclinical; Female; HIV Infections; HIV-1; Humans; Interleukin-22; Interleukins; Jurkat Cells; Lipopeptides; Male; Middle Aged; Primary Cell Culture; Pteridines; Toll-Like Receptor 2; Toll-Like Receptor 7; Virus Activation; Virus Latency; Young Adult | 2018 |
Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.
Topics: Adoptive Transfer; Animals; Anti-HIV Agents; Antibodies, Neutralizing; Antibodies, Viral; CD8 Antigens; DNA, Viral; Female; HIV Antibodies; HIV-1; Humans; Immunity, Cellular; Immunity, Innate; Macaca mulatta; Male; Pteridines; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Toll-Like Receptor 7; Viral Load | 2018 |
TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia.
Topics: Animals; Anti-Retroviral Agents; CD8-Positive T-Lymphocytes; Cytokines; Drug Therapy, Combination; Macaca mulatta; Male; Pteridines; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Toll-Like Receptor 7; Up-Regulation; Viral Load; Viremia | 2019 |
PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy.
Topics: Animals; Anti-Retroviral Agents; Antibodies; Antiviral Agents; Flow Cytometry; Macaca mulatta; Male; Programmed Cell Death 1 Receptor; Pteridines; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Toll-Like Receptor 7; Viral Load | 2019 |
Activation of HIV-specific CD8
Topics: Anti-HIV Agents; CD8-Positive T-Lymphocytes; Dose-Response Relationship, Drug; Flow Cytometry; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Pteridines | 2020 |
A TLR7 agonist activates bovine Th1 response and exerts antiviral activity against bovine leukemia virus.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antiviral Agents; Cattle; CD11c Antigen; Cells, Cultured; Enzootic Bovine Leukosis; Interferon-gamma; Lectins, C-Type; Leukemia Virus, Bovine; Lymphocyte Activation; Pteridines; Th1 Cells; Toll-Like Receptor 7; Tumor Necrosis Factor-alpha; Viral Load | 2021 |
Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Depsipeptides; Endogenous Retroviruses; Female; Histone Deacetylase Inhibitors; Humans; Imiquimod; Immunity, Innate; Mice, Nude; Ovarian Neoplasms; Pteridines; Signal Transduction; Toll-Like Receptor 7; Tumor Cells, Cultured; Viral Envelope Proteins; Virus Activation; Vorinostat; Xenograft Model Antitumor Assays | 2021 |
Antiviral effect of vesatolimod (GS-9620) against foot-and-mouth disease virus both in vitro and invivo.
Topics: Animals; Antiviral Agents; Cattle; Deer; Foot-and-Mouth Disease; Foot-and-Mouth Disease Virus; Humans; Interferon-alpha; Mice; Pteridines; Sheep; Swine; Viral Vaccines | 2022 |